1953 - Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Magdalena E. Sobieszczyk, MD, MPH

Chief, Division of Infectious Diseases
Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian Columbia University Irving Medical Center, New York, NY, USA
New York, New York, United States

Co-Author(s)

Ann R. Falsey, MD

Professor of Medicine
University of Rochester School of Medicine and Dentistry, Rochester, NY; Rochester Regional Health, Rochester, NY, USA
Rochester, New York, United States
Anne F. Luetkemeyer, MD

Professor of Medicine
Zuckerberg San Francisco General, University of California, San Francisco, CA, USA
San Francisco, California, United States
GP

Grant C. Paulsen, MD

Assistant Professor
Department of Pediatrics, University of Cincinnati College of Medicine, and Division of Pediatric Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Cincinnati, Ohio, United States
SR

Sharon A. Riddler, MD

Associate Professor of Medicine
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
MR

Merlin L. Robb, MD

Walter Reed Army Institute of Research, Silver Spring, MD, USA
Silver Spring, Maryland, United States
Charlotte-Paige M. Rolle, MD, MPH

Director of Research Operations
Orlando Immunology Center, Orlando, FL, USA
Orlando, Florida, United States
BS

Beverly E. Sha, MD

Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA
Chicago, Illinois, United States
TT

Tina Tong, MS

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Bethesda, Maryland, United States
BA

Bahar Ahani, BSC

AstraZeneca
Gaithersburg, Maryland, United States
Anastasia A. Aksyuk, PhD

Director
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, MD, United States
HB

Himanshu Bansal, MS

Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
JG

Justin A. Green, MD

Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
Cambridge, England, United Kingdom
BJ

Brett Jepson, MS

Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
JM

Jill Maaske, MD

Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
KS

Kathryn Shoemaker, MS

Senior Principal Statistician
Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
SS

Stephanie Sproule, MMath

Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
AS

Ann Marie Stanley, PhD

Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
DW

Deidre Wilkins, BSC

Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
TV

Tonya L. Villafana, PhD, MPH

AstraZeneca
Gaithersburg, Maryland, United States
EK

Elizabeth J. Kelly, PhD

AstraZeneca
Gaithersburg, Maryland, United States